Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Freeman

Plastic Surgery Bakersfield, CA Medical Doctor

NPI 1770789448 CMS profile 126617

1700 Mt. Vernon Ave., Bakersfield, CA 93306

Open in the dashboard

General payments

$5,430

203 records reported · program years 2019–2025

Research payments

$105,909

Paid to them · 167 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Freeman of Bakersfield, CA is reported in the CMS Open Payments database as having received $5,430 across 203 general payments and $105,909 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Plastic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

14 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $449 20
2025 Research $6,893 13
2024 General $1,184 31
2024 Research $11,890 19
2023 General $1,152 35
2023 Research $9,592 10
2022 General $623 37
2022 Research $15,883 32
2021 General $737 30
2021 Research $38,790 24
2020 General $683 25
2020 Research $15,149 55
2019 General $603 25
2019 Research $7,713 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Freeman
  • Plastic Surgery median
  • Middle half of Plastic Surgery
  • National median

In program year 2025, general payments to Michael Freeman were reported at $449. Among 3,701 Plastic Surgery profiles paid that year, the median was $379 and the middle half received between $138 and $1,100.

Show as a table
Year Michael Freeman Plastic Surgery median Middle half National median
2019 $603 $371 $122–$1,483 $163
2020 $683 $158 $52–$438 $114
2021 $737 $249 $87–$752 $132
2022 $623 $274 $102–$793 $149
2023 $1,152 $299 $113–$891 $160
2024 $1,184 $361 $124–$1,062 $164
2025 $449 $379 $138–$1,100 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Mentor Worldwide LLC $1,154 45 payments
  2. Smith+Nephew, Inc. $1,008 53 payments
  3. Musculoskeletal Transplant Foundation Inc. $489 14 payments
  4. AbbVie, Inc. $328 12 payments
  5. Urgo Medical North America, LLC $304 8 payments
  6. Sientra, Inc. $282 6 payments
  7. PolyNovo North America LLC $255 5 payments
  8. Stryker Corporation $236 13 payments
  9. AxoGen $232 3 payments
  10. TELA Bio, Inc. $201 5 payments
  11. Other $941 39 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,430 203 payments
Products named General payments · program years 2019–2025
  1. MENTOR MemoryGel Resterilizable Gel Sizer $428 20 payments
  2. GRAFIX PL $384 27 payments
  3. ARTOURA Breast Tissue Expander $345 16 payments
  4. OASIS $345 16 payments
  5. VASHE WOUND SOLUTION 250 ML (8.5 FL OZ) FLIP TOP CAP $304 8 payments
  6. SIENTRA HIGH STRENGTH COHESIVE SILICONE GEL BREAST IMPLANT $282 6 payments
  7. Avance Nerve Graft $232 3 payments
  8. STRAVIX $190 9 payments
  9. MENTOR CPX 2 Breast Tissue Expander $189 1 payment
  10. ALLODERM $140 7 payments
  11. Other $3,129 114 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Mentor Worldwide LLC $98,196 153 payments
  2. Medical Device Business Services, Inc. $7,713 14 payments

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

12

Median for Plastic and Reconstructive Surgery: 61

Drug cost

$94

Median for Plastic and Reconstructive Surgery: $369

Branded share of claims

100%

Median for Plastic and Reconstructive Surgery: 30%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 12 $94

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,638 Part D prescribers listed as Plastic and Reconstructive Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 32 billing codes

Paid by Medicare

$17,343

Medicare's payments for the services billed

Medicare patients

79

Average age 68

Services billed

165

64 women, 15 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Diabetes 44%
Cancer 35%
Ischemic heart disease 28%
Depression 25%
Osteoporosis 23%
COPD 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

370 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Plastic Surgery in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record